Neisseria gonorrhoeae

“Gonorrhea Alert” Intensifies Globally, says AHF

Retrieved on: 
Wednesday, July 26, 2023
Public Policy, Government, Pharmaceutical, AIDS, Health, Infectious Diseases, Communications, Social Activism, Advocacy Group Opinion, Infection, AHF, STI, Neisseria gonorrhoeae, Gonorrhea, Multimedia, HIV, AIDS Healthcare Foundation, Syphilis, World Health Organization, Disease, Vaccine, Birth control, Neisseria

Neisseria gonorrhea is exceptionally dangerous due to its resistance to multiple treatments, including new antibiotics being developed specifically for this pathogen.

Key Points: 
  • Neisseria gonorrhea is exceptionally dangerous due to its resistance to multiple treatments, including new antibiotics being developed specifically for this pathogen.
  • “Condoms are still the most cost-effective way to prevent gonorrhea, syphilis, and other STIs, including HIV – a fact people everywhere should be made aware of.
  • That starts with information campaigns at all levels of government in all countries and ensuring adequate access to free or affordable condoms.
  • Over 82 million new cases of Neisseria gonorrhea are reported in adults between the ages of 15 to 49 annually, according to the World Health Organization.

New Research Shows Promising Possibilities for At-Home Testing to Detect Sexually Transmitted Infections

Retrieved on: 
Tuesday, July 25, 2023
Vagina, Laboratory, Kaiser Permanente, Human papillomavirus infection, STI, Urine, Infection, Los Angeles County Department of Health Services, Research, Temperature, Neisseria gonorrhoeae, Doctor of Philosophy, Centers for Disease Control and Prevention, Chlamydia trachomatis, Public health, Rectum, Cervical cancer, Los Angeles County Department of Public Health, Physician, HPV, Patient, Throat, Birth control, Mineral oil, Neisseria, Chlamydia

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo. These findings could enable discreet new testing options that expand access to screening.

Key Points: 
  • ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo.
  • However, more research is needed to establish the reliability of self-collected tests.
  • For 15 study participants, the researchers evaluated 5 self-collected swabs to assess variability in swabs taken from the same individual.
  • The researchers were motivated to increase inclusivity and access to STI testing by exploring additional options for self-collection and home testing.

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023
CT, AACC, STI, Trichomonas vaginalis, Abbott, Vertically transmitted infection, QAP (Colombia), Emerging, PCR, Point-of-care testing, Infection, Neisseria gonorrhoeae, Mycoplasma, Chlamydia trachomatis, BD, Assay, RUO, Gertrude Pocte Geddes Willis, American Association for Clinical Chemistry, NG, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Medical imaging, Chlamydia, Trichomonas

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”

Gonorrhoea and syphilis diagnoses are at their highest in decades – here's what you need to know about these STIs

Retrieved on: 
Saturday, June 10, 2023
Infection, Vagina, UK Health Security Agency, Pelvic inflammatory disease, Neisseria gonorrhoeae, Penis, STI, Syphilis, Deafness, Fever, Urethra, Congenital syphilis, Skin, Incontinence, Woman, Paratriathlon, Prostate, Abdominal pain, DSM-IV codes, Partner (business rank), Gonorrhea, Pain, Treponema pallidum, Man, Dementia, Time, Vaginal discharge, Risk, Child, Chronic pain, Security agency, Ulcer, Stillbirth, Chlamydia, Water, Ageing, Pregnancy, Diagnosis, Condom, Disease, Pharmaceutical industry, Birth control, Antibiotics, Treponema

Shockingly, gonorrhoea rates are the highest they have been since records began in 1918.

Key Points: 
  • Shockingly, gonorrhoea rates are the highest they have been since records began in 1918.
  • Gonorrhoea has increased from 71,133 diagnoses per year before the pandemic to 82,592 in 2022.
  • Syphilis, which in the early 2000s was almost non-existent in the UK, has increased to 8,692 diagnoses in 2022.

What symptoms do they cause?

    • In women symptoms can be less obvious, but include a watery, green, yellow or sometimes bloodstained vaginal discharge, and pain when urinating.
    • Symptoms include fever and abdominal pain.
    • For this reason, it’s essential to get diagnosed and treated if you’re experiencing any symptoms.
    • The disease now enters a latent phase where it stays in the body while showing no symptoms.
    • This causes a range of symptoms which were dreaded in the years before effective treatment – including skin and bone disfigurations, nerve pain, heart problems, deafness, blindness, dementia and other neurological symptoms such as difficulty walking and incontinence.

Why have rates increased?

    • It’s not entirely clear why rates of syphilis and gonorrhoea have increased so rapidly in the UK.
    • Data shows that rates of gonorrhoea in particular are sensitive to social and political change, including changes to funding for sexual health services.

What can I do to protect myself?

    • If you have a symptom you’re worried about, get it checked.
    • Self-test kits for gonorrhoea and syphilis are available online in some areas or you can go to a sexual health clinic if you prefer.

New Harris Poll Finds Women Want More Education on Sexually Transmitted Infections Testing and Treatment

Retrieved on: 
Wednesday, April 19, 2023
Medical Affairs Bureau, ACOG, Vaginitis, Education, Preventive healthcare, STI, Vagina, American College of Obstetricians and Gynecologists, Trichomonas vaginalis, Infection, Health, Bacterial vaginosis, Woman, Candidiasis, Neisseria gonorrhoeae, Approximation error, Centers for Disease Control and Prevention timeline, The Harris Poll, CDC, Becton, Dickinson and Company headquarters, Chlamydia trachomatis, Patient, Clutch (eggs), Becton, American College, BDX, NYSE, BD, Birth control, Diagnosis, Chlamydia, Trichomonas, Gynaecology

The survey of more than 1,000 U.S. women over 18 years old, found that while 77% of women say they are knowledgeable about vaginal infections (including yeast infections) in general, only 60% are knowledgeable about treatment options for vaginal infections and STIs.

Key Points: 
  • The survey of more than 1,000 U.S. women over 18 years old, found that while 77% of women say they are knowledgeable about vaginal infections (including yeast infections) in general, only 60% are knowledgeable about treatment options for vaginal infections and STIs.
  • The American College of Obstetricians and Gynecologists (ACOG) recommends that women be seen by their gynecologist at least once a year.
  • However, younger women (18-34 years old) are more likely than older women (45+ years old) to have visited an urgent care facility (26% vs. 5%).
  • *Results for Asian women are based on a small sample size (n

Visby Medical™ Receives FDA Clearance and CLIA Waiver for Second Generation Sexual Health Test for Women

Retrieved on: 
Tuesday, March 14, 2023
SAN, Pharmacy, Patient, Korea Disease Control and Prevention Agency, Food, Visby, STI, Associate, Neisseria gonorrhoeae, PCR, Gonorrhea, Trichomonas vaginalis, Risk, Prevention, Polymerase chain reaction, Woman, Workflow, Education, Health, Chlamydia trachomatis, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diagnosis, CLIA, POC, Stanford University, Pelvic inflammatory disease, Pharmaceutical industry, Birth control, Operation, Medicine, Neisseria, Trichomonas, Chlamydia

The Visby Medical Sexual Health test is a fast, polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.

Key Points: 
  • The Visby Medical Sexual Health test is a fast, polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.
  • The CLIA-waived, Sexual Health POC test provides accurate results in under 30 minutes, enabling clinicians to test, talk and accurately treat with confidence in a single patient visit.
  • "The Visby Sexual Health Test has been a game changer for us.
  • The Visby test is a win-win, helping fight antibiotic resistance as well as the spread of untreated infection, while empowering patients to engage health services with greater confidence."

Microbix Supporting Australian Point-of-Care Testing Program

Retrieved on: 
Wednesday, March 1, 2023
TSX, Test management, Gertrude Pocte Geddes Willis, Diagnosis, Neisseria gonorrhoeae, OTCQX, Chlamydia trachomatis, QAP (Colombia), Business development, STI, Trichomonas vaginalis, MDX, SVP, Health, Point-of-care testing, Medical device, Trichomonas, Chlamydia

MISSISSAUGA, Ontario, March 01, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products (“QAPs™”) are now supporting test accuracy within a program to provide Point-of-Care Testing (“PoCT”) for Sexually-Transmitted Infections (“STIs”) in remote communities across Australia.

Key Points: 
  • MISSISSAUGA, Ontario, March 01, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products (“QAPs™”) are now supporting test accuracy within a program to provide Point-of-Care Testing (“PoCT”) for Sexually-Transmitted Infections (“STIs”) in remote communities across Australia.
  • It is therefore honoured to be supporting this Australian program for STI testing in remote communities, which Microbix believes is providing a worldwide model for helping underserved populations.
  • Philip Hill, General Manager of r-Biopharm Australia commented, “r-Biopharm is pleased that the program will be delivering world-class diagnostic testing to some of the most remote populations in Australia.
  • This program, supported by PROCEEDxFLOQ QAPs, should help to provide the kind of testing needed in these Australian communities.”
    Microbix’s FLOQSwab-based QAPs support both STIs and other disease categories, with the full catalogue available at https://microbix.com and purchase enquiries directed to [email protected] .

Thermo Fisher Scientific Launches TrueMark STI Select Panel

Retrieved on: 
Wednesday, February 8, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Alternative Energy, Environment, Energy, Science, STI, Thermo Fisher Scientific, Neisseria gonorrhoeae, Applied Biosystems, Korea Disease Control and Prevention Agency, Mycoplasma, PCR, MagMax, Genetic testing, Trichomonas vaginalis, Ribonuclease P, Chlamydia trachomatis, CDC, Syphilis, Genetic, Gonorrhea, Polymerase chain reaction, Mycoplasma genitalium, Vaccine, Neisseria, Chlamydia, Trichomonas

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.
  • The Applied Biosystems TrueMark STI Select Panel simultaneously tests for the four common STIs on the same panel, helping labs save time that would have been otherwise needed to run each on their own.
  • The TrueMark STI Select Panel is sold as a combo kit, which includes the STI panel assay and master mix; positive controls are also included for added accuracy and efficiency.
  • For more information on Thermo Fisher’s TrueMark STI Panel, please visit: https://www.thermofisher.com/truemarkstiselectpanel
    For Research Use Only.

2023 Healthcare Trend: Growth in $21 Billion Molecular Diagnostics Market

Retrieved on: 
Tuesday, January 3, 2023
Knowledge, Infection, Roche Diagnostics, RT, COVID, Knowledge-centered support, Gen-Probe, BD (company), Growth, COVID-19, Tuberculosis, Publishing, Neisseria gonorrhoeae, HIV, Coagulation, IVD, Cancer, Chlamydia trachomatis, Pharmaceutical industry, Science

ARLINGTON, Va., Jan. 3, 2023 /PRNewswire-PRWeb/ -- There is a market in excess of $21 billion for molecular testing technologies, reveals medical market research publisher Kalorama Information in The World Market for Molecular Diagnostics Tests, 11th Edition, a recent report added to the firm's Knowledge Center subscription. The majority of the market is COVID-19, but there remains a $10 billion dollar market for all other molecular in vitro diagnostics (IVD).

Key Points: 
  • ARLINGTON, Va., Jan. 3, 2023 /PRNewswire-PRWeb/ -- There is a market in excess of $21 billion for molecular testing technologies, reveals medical market research publisher Kalorama Information in The World Market for Molecular Diagnostics Tests, 11th Edition , a recent report added to the firm's Knowledge Center subscription .
  • The majority of the market is COVID-19, but there remains a $10 billion dollar market for all other molecular in vitro diagnostics (IVD).
  • Kalorama Information estimates a $11 billion dollar market for 2022 for COVID-19 molecular diagnostics testing.
  • "Recent growth in molecular diagnostics methods has also been coming from inherited diseases, cancer, coagulation, and other areas."

Infectious Disease Diagnostics Market by Product, Test Type, Disease, Technology, End User and Region - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 21, 2022
Health, Infectious Diseases, Hospital, HIV, Neisseria gonorrhoeae, Eyeish, POC, Infection, Clifton Springs Hospital & Clinic, Immunoassay, Hepatitis, PCR, Instrument, Syphilis, HPV, Lab, USD, Chlamydia trachomatis, Personal Software Services, Growth, Degenerative disease, Reagent, COVID-19, Hospital-acquired infection, NGS, Product-service system, Vaccine, Medical device, Disease, Software, Chlamydia, Tuberculosis

The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.

Key Points: 
  • The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.
  • The reagents, kits, and consumables accounted for the largest market share in the infectious disease diagnostics market, by product & service, during the forecast period
    The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services.
  • The reagents, kits, and consumables segment accounted for the largest market share in the infectious disease diagnostics market in 2021.
  • Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users.